NCT06547554View on ClinicalTrials.gov

A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 4, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Bacterial Infections
Interventions
DRUG

Xeruborbactam

Experimental

DRUG

Cefiderocol

Experimental

DRUG

Xeruborbactam/Cefiderocol

A combination of Xeruborbactam and Cefiderocol.

DRUG

Dextrose 5% in water

Placebo

Trial Locations (1)

55114

RECRUITING

Minneapolis Clinic, Minneapolis

All Listed Sponsors
collaborator

Shionogi Inc.

INDUSTRY

collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Qpex Biopharma, Inc.

INDUSTRY